Table 2.

Adverse events reported in clinical study (n=12)

Event	SNK01 with GC (n=6)		SNK01 with C/GC (n=6)
	All grade AEs	≥3 grade AEs	All grade AEs	≥3 grade AEs
All AEs	6 (100)	3 (50.0)	6 (100)	2 (33.3)
AEs occurring in ≥2 patients
Neutropenia	5 (83.3)	3 (50.0)	4 (66.7)	2 (33.3)
Anemia	3 (50.0)	1 (16.7)	2 (33.3)	0 (0.0)
Fever	3 (50.0)	0 (0.0)	1 (16.7)	0 (0.0)
Skin rash	2 (33.3)	0 (0.0)	6 (100)	0 (0.0)
Diarrhea	2 (33.3)	0 (0.0)	1 (16.7)	0 (0.0)
Thrombocytopenia	2 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)
Alopecia	2 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)
Constipation	1 (16.7)	0 (0.0)	1 (16.7)	0 (0.0)
Anorexia	1 (16.7)	0 (0.0)	1 (16.7)	0 (0.0)
Paronychia	0 (0.0)	0 (0.0)	5 (83.3)	0 (0.0)
Hypomagnesemia	0 (0.0)	0 (0.0)	2 (33.3)	0 (0.0)
SNK01-related AEs*	2 (33.3)	0 (0.0)	1 (16.7)	0 (0.0)

Data are presented as number (percentage).

*All the SNK01-related AEs were fever.

AE, adverse event; C/GC, cetuximab/GC; GC, gemcitabine/carboplatin.